Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel-Reference-Cited by-同舟云学术

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

Published:2008-01 Issue:1 Volume:58 Page:25-32
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Halevy Sima,Ghislain Pierre-Dominique,Mockenhaupt Maja,Fagot Jean-Paul,Bouwes Bavinck Jan Nico,Sidoroff Alexis,Naldi Luigi,Dunant Ariane,Viboud Cecile,Roujeau Jean-Claude

Publisher

Elsevier BV

Subject

Dermatology

Reference29 articles.

1. Sweetman S, editor. Martindale: the complete drug reference [database online]. London: Pharmaceutical Press; 2006. Electronic version; Greenwood Village, Colo: Thomson Micromedex. Edition expires September 2006.

2. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis;Aubock;Br Med J,1985

3. Allopurinol hypersensitivity syndrome: a review;Arellano;Ann Pharmacother,1993

4. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study;Auquier-Dunant;Arch Dermatol,2002

5. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme;Bastuji-Garin;Arch Dermatol,1993

Cited by 377 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperuricemia and its related diseases: mechanisms and advances in therapy;Signal Transduction and Targeted Therapy;2024-08-28

2. Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout;Journal of Medicinal Chemistry;2024-08-07

3. The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) – Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions;World Allergy Organization Journal;2024-08

4. Advances in Clinical Pharmacogenomics and Prevention of Severe Cutaneous Adverse Drug Reactions in the Era of Precision Medicine;Personalized Medicine - New Perspectives [Working Title];2024-07-17

5. Hyperuricemia – consequences of not initiating therapy. Benefits and drawbacks of treatment;Rheumatology;2024-07-01